BR112014000360A2 - análogos de heterociclil pirimidina como inibidores jak - Google Patents
análogos de heterociclil pirimidina como inibidores jakInfo
- Publication number
- BR112014000360A2 BR112014000360A2 BR112014000360A BR112014000360A BR112014000360A2 BR 112014000360 A2 BR112014000360 A2 BR 112014000360A2 BR 112014000360 A BR112014000360 A BR 112014000360A BR 112014000360 A BR112014000360 A BR 112014000360A BR 112014000360 A2 BR112014000360 A2 BR 112014000360A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrimidine analogs
- jak inhibitors
- heterocyclyl
- heterocyclyl pyrimidine
- jak
- Prior art date
Links
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- -1 heterocyclyl pyrimidine analogs Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11175807 | 2011-07-28 | ||
| US201261635921P | 2012-04-20 | 2012-04-20 | |
| PCT/EP2012/064515 WO2013014162A1 (en) | 2011-07-28 | 2012-07-24 | Heterocyclyl pyrimidine analogues as jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112014000360A2 true BR112014000360A2 (pt) | 2017-02-14 |
Family
ID=47600533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014000360A BR112014000360A2 (pt) | 2011-07-28 | 2012-07-24 | análogos de heterociclil pirimidina como inibidores jak |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20140179664A1 (enExample) |
| EP (1) | EP2736901A1 (enExample) |
| JP (1) | JP2014521623A (enExample) |
| KR (1) | KR20140047092A (enExample) |
| CN (1) | CN103781780B (enExample) |
| AU (1) | AU2012288892B2 (enExample) |
| BR (1) | BR112014000360A2 (enExample) |
| CA (1) | CA2843195A1 (enExample) |
| WO (1) | WO2013014162A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102480966B (zh) | 2009-06-12 | 2015-09-16 | 达娜-法勃肿瘤研究所公司 | 融合的杂环化合物及其用途 |
| EP2822935B1 (en) | 2011-11-17 | 2019-05-15 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
| WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| ES2676734T3 (es) | 2013-10-18 | 2018-07-24 | Syros Pharmaceuticals, Inc. | Compuestos heteroatómicos útiles para el tratamiento de enfermedades proliferativas |
| WO2015164604A1 (en) * | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| US10870651B2 (en) | 2014-12-23 | 2020-12-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| AU2016243529B2 (en) | 2015-03-27 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| JP7028766B2 (ja) | 2015-09-09 | 2022-03-02 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
| HK1251475A1 (zh) | 2015-10-08 | 2019-02-01 | Macrogenics, Inc. | 用於癌症治疗的联合疗法 |
| WO2017087905A1 (en) | 2015-11-20 | 2017-05-26 | Denali Therapeutics Inc. | Compound, compositions, and methods |
| US11028080B2 (en) | 2016-03-11 | 2021-06-08 | Denali Therapeutics Inc. | Substituted pyrimidines as LRKK2 inhibitors |
| CN109311857B (zh) | 2016-06-16 | 2021-11-12 | 戴纳立制药公司 | 作为用于治疗神经退化性病症的lrrk2抑制剂的嘧啶-2-基氨基-1h-吡唑 |
| EP3686197B1 (en) * | 2017-09-21 | 2023-06-21 | Beijing Scitech-MQ Pharmaceuticals Limited | 2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof |
| CN109535132B (zh) * | 2017-09-21 | 2021-07-20 | 北京赛特明强医药科技有限公司 | 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用 |
| AU2019295632B2 (en) | 2018-06-25 | 2025-03-06 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| CN110734427B (zh) * | 2018-07-20 | 2021-01-15 | 北京赛特明强医药科技有限公司 | 含烯基的嘧啶甲酰胺类化合物、组合物及其应用 |
| CN110845476B (zh) * | 2018-08-21 | 2022-11-18 | 上海和誉生物医药科技有限公司 | 一种高选择性csf1r抑制剂、其制备方法和在药学上的应用 |
| US12415816B2 (en) | 2018-11-07 | 2025-09-16 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| WO2020118683A1 (en) * | 2018-12-14 | 2020-06-18 | Lynk Pharmaceuticals Co. Ltd. | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof |
| JP7660063B2 (ja) | 2018-12-28 | 2025-04-10 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用 |
| EP4295846A3 (en) * | 2019-05-10 | 2024-02-28 | Deciphera Pharmaceuticals, LLC | Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| PE20220597A1 (es) | 2019-05-10 | 2022-04-22 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos |
| CA3143489A1 (en) | 2019-06-17 | 2020-12-24 | Deciphera Pharmaceuticals, Llc | Aminopyrimidine amide autophagy inhibitors and methods of use thereof |
| IL293965A (en) | 2019-12-19 | 2022-08-01 | Janssen Pharmaceutica Nv | History of Spiro straight chain transformed |
| WO2024239282A1 (zh) * | 2023-05-24 | 2024-11-28 | 凌科药业(杭州)有限公司 | 一种药物组合物、外用制剂及其制备方法、应用 |
| CN120917009A (zh) * | 2024-01-26 | 2025-11-07 | 凌科药业(杭州)有限公司 | 一种吡唑基-氨基-嘧啶基衍生物的苯甲酰胺的晶型、制备方法及应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69837529T2 (de) | 1997-02-12 | 2007-07-26 | Electrophoretics Ltd., Cobham | Proteinmarker für lungenkrebs und deren verwendung |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| WO1999031073A1 (en) * | 1997-12-15 | 1999-06-24 | Yamanouchi Pharmaceutical Co., Ltd. | Novel pyrimidine-5-carboxamide derivatives |
| EE05345B1 (et) | 1999-02-10 | 2010-10-15 | Astrazeneca Ab | Kinasoliini derivaadid angiogeneesi inhibiitoritena |
| KR100881105B1 (ko) | 1999-11-05 | 2009-02-02 | 아스트라제네카 아베 | Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체 |
| UA72290C2 (uk) | 1999-12-10 | 2005-02-15 | Пфайзер Продактс Інк. | СПОЛУКИ ПІРОЛО[2.3-d]ПІРИМІДИНУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), СПОСІБ ІНГІБУВАННЯ ПРОТЕЇНКІНАЗ АБО JANUS КІНАЗИ 3 (ВАРІАНТИ) |
| ATE369359T1 (de) | 2000-02-15 | 2007-08-15 | Sugen Inc | Pyrrol substituierte indolin-2-on protein kinase inhibitoren |
| US20080194606A1 (en) * | 2005-05-05 | 2008-08-14 | Astrazeneca | Pyrazolyl-Amino-Substituted Pyrimidines and Their Use in the Treatment of Cancer |
| PL1891446T3 (pl) | 2005-06-14 | 2013-08-30 | Cellzome Gmbh | Sposób identyfikacji nowych związków oddziałujących z enzymami |
| GB0605691D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
| DE602006004196D1 (de) | 2006-06-01 | 2009-01-22 | Cellzome Ag | Verfahren zur Identifizierung von mit ZAP-70 wechselwirkenden Molekülen und zur ZAP-70-Reinigung |
| WO2008009458A1 (en) | 2006-07-21 | 2008-01-24 | Novartis Ag | 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors |
| MX2009005194A (es) | 2006-11-16 | 2009-11-10 | Pharmacopeia Llc | Derivados de purina 7-sustituidos para inmunosupresion. |
| US7947698B2 (en) | 2007-03-23 | 2011-05-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| US7834024B2 (en) | 2007-03-26 | 2010-11-16 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| WO2008129380A1 (en) * | 2007-04-18 | 2008-10-30 | Pfizer Products Inc. | Sulfonyl amide derivatives for the treatment of abnormal cell growth |
| WO2008132502A1 (en) * | 2007-04-25 | 2008-11-06 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer |
| JP2010532756A (ja) | 2007-07-06 | 2010-10-14 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法 |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| EP2419423A1 (en) | 2009-04-14 | 2012-02-22 | Cellzome Limited | Fluoro substituted pyrimidine compounds as jak3 inhibitors |
| CA2775009A1 (en) * | 2009-10-20 | 2011-04-28 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors |
-
2012
- 2012-07-24 BR BR112014000360A patent/BR112014000360A2/pt not_active IP Right Cessation
- 2012-07-24 EP EP12738141.6A patent/EP2736901A1/en not_active Withdrawn
- 2012-07-24 AU AU2012288892A patent/AU2012288892B2/en not_active Expired - Fee Related
- 2012-07-24 CN CN201280043720.5A patent/CN103781780B/zh not_active Expired - Fee Related
- 2012-07-24 CA CA2843195A patent/CA2843195A1/en not_active Abandoned
- 2012-07-24 KR KR1020147001951A patent/KR20140047092A/ko not_active Withdrawn
- 2012-07-24 WO PCT/EP2012/064515 patent/WO2013014162A1/en not_active Ceased
- 2012-07-24 JP JP2014522067A patent/JP2014521623A/ja active Pending
- 2012-07-24 US US14/234,662 patent/US20140179664A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2843195A1 (en) | 2013-01-31 |
| AU2012288892A1 (en) | 2014-02-20 |
| JP2014521623A (ja) | 2014-08-28 |
| CN103781780A (zh) | 2014-05-07 |
| AU2012288892B2 (en) | 2016-04-21 |
| WO2013014162A1 (en) | 2013-01-31 |
| CN103781780B (zh) | 2015-11-25 |
| KR20140047092A (ko) | 2014-04-21 |
| EP2736901A1 (en) | 2014-06-04 |
| US20140179664A1 (en) | 2014-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014000360A2 (pt) | análogos de heterociclil pirimidina como inibidores jak | |
| CO6920291A2 (es) | 3-pirmidin-4-il-oxazolidin-2-onas como inhibidores de la idhmutante | |
| CO6852079A2 (es) | Derivados de piridin-2(1h)-ona como inhibidores de jak | |
| JP2013525366A5 (ja) | ピリミジンジオン抗ウイルス性化合物 | |
| SMT201500197B (it) | Imidazolilimidazoli condensati come composti antivirali | |
| CO6880068A2 (es) | Aminoquinazolinas como inhibidores de quinasa | |
| BR112014007781A2 (pt) | compostos anti-virais | |
| DK2834236T3 (da) | Heterocyclylforbindelser | |
| CO6811864A2 (es) | Piridin-2-amidas útiles como agonistas de cb2 | |
| BR112013024378A2 (pt) | novos derivados de pirimidina | |
| EP2675909A4 (en) | GLUCOSYLSTEVIA COMPOSITION | |
| EP2720561A4 (en) | Stevia-COMPOSITION | |
| CR20140147A (es) | Inhibidores de aplicación viral | |
| UY34092A (es) | Nuevos compuestos como inhibidores de jak | |
| EP2713762A4 (en) | Stevia-COMPOSITION | |
| BR112014015681A2 (pt) | análogos de glucagon | |
| EP2701768A4 (en) | NOSE FLUSH TOP | |
| CU24164B1 (es) | Inhibidores sustituidos de acetil-coa carboxilasa | |
| BR112013024076A2 (pt) | análogos de glucagon | |
| BR112014013850A2 (pt) | conjunto de prateleiras | |
| EP2707101A4 (en) | Proteostasis-REGULATORS | |
| CO6900144A2 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| CO6791617A2 (es) | Combinaciones de compuestos activos | |
| BR112014007599A2 (pt) | compostos anti-virais | |
| EP2797752A4 (en) | CUTTING MEDIA |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |